ValGenesis and AUSTAR have partnered to deploy digital, risk-based solutions for life sciences companies in China.
AUSTAR is a technology-based pharmaceutical engineering solutions provider with deep understanding of industry regulations and processes. The company is committed to helping clients improve process and operational effectiveness through boosting global drug safety and efficacy to protect and promote human health.
ValGenesis' end-to-end digital validation platform, which includes its flagship VLMS offering, helps the world's leading life sciences companies enable stronger compliance, enforce standardisation, and further digital transformation across manufacturing operations.
Through the cooperation with ValGenesis, we will provide more effective information solutions and consulting services
- Lena Wang, AUSTAR's VP
ValGenesis and AUSTAR recently implemented ValGenesis iRisk at two large drug manufacturing centres in China, helping them strengthen risk and compliance across development and manufacturing operations. ValGenesis iRisk helps companies effectively assess and manage risk throughout a product's lifecycle in a fully digital, purpose-built application.
"ValGenesis and AUSTAR are committed to helping companies assess their risks the way they need to assess them to remain compliant," said Bo Olsen, ValGenesis' SVP of Partners. "iRisk unifies all risk-related activities in one powerful platform, standardising risk management practices across an organisation. We look forward to taking this powerful solution to more life sciences companies in China, with AUSTAR."
"AUSTAR is committed to serving pharmaceutical enterprises to achieve compliance, quality improvement and risk management," said Lena Wang, AUSTAR's VP. "Through the cooperation with ValGenesis, we will provide more effective information solutions and consulting services."
